HIVers considering switching from a protease inhibitor to an NNRTI should talk with their doctors about an alarming possibility: a relapse of Kaposi's sarcoma. A report in the Journal of Acquired Immune Deficiency Syndromes has shown that 17.6% of HIVers with a previous case of KS experienced a relapse when switching from a PI to an NNRTI. The researchers say the relapses may be due to the 'anti-angiogenic, anti-KS, and antitumor effects' associated with PIs that are diminished when other anti-HIV drugs are taken.
